VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study

VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study

The prospective multicenter COMET trial followed a cohort of 306 consecutive metastatic breast cancer patients receiving bevacizumab and paclitaxel as first-line chemotherapy. This study was intended to identify and validate reliable biomarkers to better predict bevacizumab treatment outcomes and al...

Full description

Bibliographic Details
Main Authors: Jocelyn Gal, Gérard Milano, Patrick Brest, Nathalie Ebran, Julia Gilhodes, Laurence Llorca, Coraline Dubot, Gilles Romieu, Isabelle Desmoulins, Etienne Brain, Anthony Goncalves, Jean-Marc Ferrero, Paul-Henri Cottu, Marc Debled, Olivier Tredan, Emmanuel Chamorey, Marco Carlo Merlano, Jérôme Lemonnier, Marie-Christine Etienne-Grimaldi, Jean-Yves Pierga
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Pharmaceuticals
Subjects:
breast cancer
precision medicine
pharmacogenetics
bevacizumab
SNP
VEGF
Online Access:https://www.mdpi.com/1424-8247/13/11/414

Internet

https://www.mdpi.com/1424-8247/13/11/414

Similar Items